Comparison of COVID-19 and influenza characteristics.
Comparison of COVID-19 and influenza characteristics.
复制标题
DOI：
10.1631/jzus.b2000479
复制
发表时间：
2021-02-15
期刊：
影响因子：
--
通讯作者：
Tao X
中科院分区：
文献类型：
--
作者：
Bai Y;Tao X
2019冠状病毒病（COVID-19）的出现不仅对全球人民的健康构成严重威胁，也影响了全球经济。COVID-19疫情于二零一九年十二月开始爆发，与流感季节同时爆发。然而，由于COVID-19和流感的治疗和发病情况不同，因此根据其各自的早期特征准确区分这两种不同的呼吸道感染非常重要。我们查阅了中华人民共和国国家卫生健康委员会、中国疾病预防控制中心发布的官方文件和新闻（中国疾控中心）、美国疾控中心、世界卫生组织（WHO），同时检索PubMed、Web of Science、Excerpta Medica数据库（Embase）、中国知网（CNKI）、万方、预印bioRxiv和medRxiv数据库，用于从最早可用日期至2020年10月3日的文件和指南。我们获得了关于COVID-19和流感的最新信息，并总结和比较了它们的生物学特征，流行病学，临床表现，病理机制，治疗方法和预后因素。我们表明，尽管COVID-19和流感在许多方面不同，但也有许多相似之处;因此，除了使用基于核酸的聚合酶链反应（PCR）和基于抗体的方法外，临床医生和流行病学家应该在早期阶段使用各自的特征区分两者。我们应该利用其他流行病的经验，为COVID-19的治疗和预防提供额外的指导。
The emergence of coronavirus disease 2019 (COVID-19) not only poses a serious threat to the health of people worldwide but also affects the global economy. The outbreak of COVID-19 began in December 2019, at the same time as the influenza season. However, as the treatments and prognoses of COVID-19 and influenza are different, it is important to accurately differentiate these two different respiratory tract infections on the basis of their respective early-stage characteristics. We reviewed official documents and news released by the National Health Commission of the People’s Republic of China, the Chinese Center for Disease Control and Prevention (China CDC), the United States CDC, and the World Health Organization (WHO), and we also searched the PubMed, Web of Science, Excerpta Medica database (Embase), China National Knowledge Infrastructure (CNKI), Wanfang, preprinted bioRxiv and medRxiv databases for documents and guidelines from earliest available date up until October 3rd, 2020. We obtained the latest information about COVID-19 and influenza and summarized and compared their biological characteristics, epidemiology, clinical manifestations, pathological mechanisms, treatments, and prognostic factors. We show that although COVID-19 and influenza are different in many ways, there are numerous similarities; thus, in addition to using nucleic acid-based polymerase chain reaction (PCR) and antibody-based approaches, clinicians and epidemiologists should distinguish between the two using their respective characteristics in early stages. We should utilize experiences from other epidemics to provide additional guidance for the treatment and prevention of COVID-19.